Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value

Volume: 18, Issue: 10, Pages: 1844 - 1851
Published: Oct 1, 2019
Abstract
Immune-checkpoint blockade (ICB) uses antibody targeting of specific inhibitory receptors and ligands. The major limitations of ICB, such as high cost, limited success rate, and immune-related adverse events (irAE), highlight the need for predictive biomarkers. We analyzed pre-immunotherapy and post-immunotherapy serum samples of 24 patients treated with pembrolizumab for changes in PD-1 and over 1,000 additional protein markers using a...
Paper Details
Title
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value
Published Date
Oct 1, 2019
Volume
18
Issue
10
Pages
1844 - 1851
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.